ALD-话题@MedSci

#ALD#

59篇内容 | 2177人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2212304, encodeId=d26f221230418, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a> <a href='/topic/show?id=487a8244984' target=_blank style='color:#2F92EE;'>#肾上腺脑白质营养不良#</a>, objectTitle=原以为孩子只是注意力不集中，只是反应慢些，没想到是……, objectType=article, longId=832150, objectId=0fcd83215030, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240627/1719492929169_8538692.jpg, objectUrl=/article/show_article.do?id=0fcd83215030, replyNumber=0, likeNumber=57, createdTime=2024-06-29, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=0fcd83215030, moduleTitle=原以为孩子只是注意力不集中，只是反应慢些，没想到是……, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0fcd83215030)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1469437, encodeId=d1ce146943e9c, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=Nature Chemical Biology：结直肠癌治疗新靶点——ALDH1B1, objectType=article, longId=732005, objectId=00eae3200526, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00eae3200526, replyNumber=0, likeNumber=69, createdTime=2022-07-12, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00eae3200526, moduleTitle=Nature Chemical Biology：结直肠癌治疗新靶点——ALDH1B1, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00eae3200526)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469436, encodeId=9516146943601, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=Eur Urol：Bempegaldesleukin加Nivolumab用于一线转移性尿路上皮癌效果如何？, objectType=article, longId=730487, objectId=eb89e30487a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb89e30487a4, replyNumber=0, likeNumber=0, createdTime=2022-06-27, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb89e30487a4, moduleTitle=Eur Urol：Bempegaldesleukin加Nivolumab用于一线转移性尿路上皮癌效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb89e30487a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469435, encodeId=40941469435a5, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=JCO：口服SERD艾拉司群治疗ER+/HER2-晚期乳腺癌安全有效！EMERALD III期临床最新数据出炉！, objectType=article, longId=727998, objectId=c0e7e2799863, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0e7e2799863, replyNumber=0, likeNumber=91, createdTime=2022-05-29, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0e7e2799863, moduleTitle=JCO：口服SERD艾拉司群治疗ER+/HER2-晚期乳腺癌安全有效！EMERALD III期临床最新数据出炉！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0e7e2799863)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469434, encodeId=b379146943491, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=J Clin Oncol：选择性雌激素受体降解剂（Elacestrant）对比标准内分泌治疗ER+/HR-晚期乳腺癌的疗效：III期临床研究EMERALD, objectType=article, longId=727795, objectId=19a7e27795a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19a7e27795a3, replyNumber=0, likeNumber=65, createdTime=2022-05-26, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19a7e27795a3, moduleTitle=J Clin Oncol：选择性雌激素受体降解剂（Elacestrant）对比标准内分泌治疗ER+/HR-晚期乳腺癌的疗效：III期临床研究EMERALD, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19a7e27795a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469433, encodeId=c51d146943368, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=J Immunother Cancer：Bempegaldesleukin联合纳武单抗一线治疗晚期肾细胞癌, objectType=article, longId=725499, objectId=bec0e25499db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bec0e25499db, replyNumber=0, likeNumber=73, createdTime=2022-04-28, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bec0e25499db, moduleTitle=J Immunother Cancer：Bempegaldesleukin联合纳武单抗一线治疗晚期肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bec0e25499db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469432, encodeId=9a7f1469432f4, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=Neurology：2017年和2010年修订的McDonald标准在预测临床孤立综合征后MS诊断中的表现, objectType=article, longId=219548, objectId=6dd42195487f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6dd42195487f, replyNumber=0, likeNumber=86, createdTime=2021-11-01, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6dd42195487f, moduleTitle=Neurology：2017年和2010年修订的McDonald标准在预测临床孤立综合征后MS诊断中的表现, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6dd42195487f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469431, encodeId=4fb1146943158, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=J Clin Oncol：伊布替尼（Ibrutinib）+利妥昔单抗对比安慰剂+ 利妥昔单抗治疗Waldenstrm巨球蛋白血症的疗效:来自随机III期iNNOVATE研究最终分析结果, objectType=article, longId=218141, objectId=54be2181415e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54be2181415e, replyNumber=0, likeNumber=56, createdTime=2021-10-07, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54be2181415e, moduleTitle=J Clin Oncol：伊布替尼（Ibrutinib）+利妥昔单抗对比安慰剂+ 利妥昔单抗治疗Waldenstrm巨球蛋白血症的疗效:来自随机III期iNNOVATE研究最终分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54be2181415e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469430, encodeId=ed6b14694304d, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=Clin Cancer Res：国产BTK抑制剂泽布替尼治疗难治/复发性Waldenström巨球蛋白血症的疗效和安全性, objectType=article, longId=216579, objectId=57b22165e959, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=57b22165e959, replyNumber=0, likeNumber=84, createdTime=2021-09-03, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=57b22165e959, moduleTitle=Clin Cancer Res：国产BTK抑制剂泽布替尼治疗难治/复发性Waldenström巨球蛋白血症的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=57b22165e959)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469429, encodeId=337b146942921, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=Clin Cancer Res：BTK抑制剂Zanubrutinib治疗复发/难治性Waldenströms巨球蛋白血症(WM)的疗效, objectType=article, longId=214279, objectId=44752142e9a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44752142e9a0, replyNumber=0, likeNumber=67, createdTime=2021-07-17, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44752142e9a0, moduleTitle=Clin Cancer Res：BTK抑制剂Zanubrutinib治疗复发/难治性Waldenströms巨球蛋白血症(WM)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=44752142e9a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469428, encodeId=d9d71469428b4, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=J Clin Oncol：Bempegaldesleukin 联合纳武利尤单抗（Nivolumab）一线治疗转移性黑色素瘤, objectType=article, longId=214261, objectId=08ac21426112, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08ac21426112, replyNumber=0, likeNumber=52, createdTime=2021-07-17, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08ac21426112, moduleTitle=J Clin Oncol：Bempegaldesleukin 联合纳武利尤单抗（Nivolumab）一线治疗转移性黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08ac21426112)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469427, encodeId=8b25146942e04, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=美国FDA接受BRUKINSA（Zanubrutinib）治疗Waldenström巨球蛋白血症的补充新药申请, objectType=article, longId=207300, objectId=047f20e30032, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=047f20e30032, replyNumber=0, likeNumber=79, createdTime=2021-02-20, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=047f20e30032, moduleTitle=美国FDA接受BRUKINSA（Zanubrutinib）治疗Waldenström巨球蛋白血症的补充新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=047f20e30032)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469426, encodeId=31b81469426d8, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=欧洲委员会授予CLR 131治疗Waldenstrom巨球蛋白血症的“孤儿药资格”, objectType=article, longId=206366, objectId=b3d82063663c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3d82063663c, replyNumber=0, likeNumber=73, createdTime=2021-01-30, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3d82063663c, moduleTitle=欧洲委员会授予CLR 131治疗Waldenstrom巨球蛋白血症的“孤儿药资格”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3d82063663c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469425, encodeId=6d211469425ec, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=Gastroenterology：工程化FGF-19类似物Aldafermin治疗NSAH II期临床获得成功, objectType=article, longId=205638, objectId=cd2320563849, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd2320563849, replyNumber=0, likeNumber=74, createdTime=2021-01-13, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd2320563849, moduleTitle=Gastroenterology：工程化FGF-19类似物Aldafermin治疗NSAH II期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd2320563849)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469424, encodeId=3f2e1469424b7, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=Bluebird突破性基因疗法Lenti-D申请上市！改善致死罕见病CALD患者长期生存结局, objectType=article, longId=201693, objectId=ec9320169308, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec9320169308, replyNumber=0, likeNumber=65, createdTime=2020-10-06, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec9320169308, moduleTitle=Bluebird突破性基因疗法Lenti-D申请上市！改善致死罕见病CALD患者长期生存结局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec9320169308)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469423, encodeId=48ce1469423cb, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=重组白介素2 Aldesleukin治疗肌萎缩性侧索硬化症，获得FDA的孤儿药称号, objectType=article, longId=197524, objectId=53cf19e5243c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=53cf19e5243c, replyNumber=0, likeNumber=75, createdTime=2020-07-16, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=53cf19e5243c, moduleTitle=重组白介素2 Aldesleukin治疗肌萎缩性侧索硬化症，获得FDA的孤儿药称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=53cf19e5243c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469422, encodeId=caa0146942255, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=Waldenström巨球蛋白血症患者同时存在皮肤巨球蛋白病和Buschke硬肿病, objectType=article, longId=195963, objectId=cec719596323, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cec719596323, replyNumber=0, likeNumber=75, createdTime=2020-06-18, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cec719596323, moduleTitle=Waldenström巨球蛋白血症患者同时存在皮肤巨球蛋白病和Buschke硬肿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cec719596323)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469421, encodeId=2801146942151, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=Blood：基于代谢状态的癌症治疗方法——Aldh3a2抑制, objectType=article, longId=195138, objectId=a3c719513884, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3c719513884, replyNumber=0, likeNumber=0, createdTime=2020-06-03, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3c719513884, moduleTitle=Blood：基于代谢状态的癌症治疗方法——Aldh3a2抑制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3c719513884)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469420, encodeId=84001469420f5, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=Galderma的新型透明质酸填充剂Rystylane Kysse，获得FDA批准用于丰唇, objectType=article, longId=193590, objectId=16b6193590e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16b6193590e7, replyNumber=0, likeNumber=116, createdTime=2020-05-08, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16b6193590e7, moduleTitle=Galderma的新型透明质酸填充剂Rystylane Kysse，获得FDA批准用于丰唇, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16b6193590e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469419, encodeId=2430146941985, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=Blood：造血细胞移植治疗Wiskott-Aldrich综合征的预后, objectType=article, longId=192513, objectId=e0d519251302, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0d519251302, replyNumber=0, likeNumber=0, createdTime=2020-04-20, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0d519251302, moduleTitle=Blood：造血细胞移植治疗Wiskott-Aldrich综合征的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0d519251302)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ALD

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#ALD# #肾上腺脑白质营养不良#

原以为孩子只是注意力不集中，只是反应慢些，没想到是……

2024-06-29发表于上海

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

Nature Chemical Biology：结直肠癌治疗新靶点——ALDH1B1

2022-07-12

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

Eur Urol：Bempegaldesleukin加Nivolumab用于一线转移性尿路上皮癌效果如何？

2022-06-27

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

JCO：口服SERD艾拉司群治疗ER+/HER2-晚期乳腺癌安全有效！EMERALD III期临床最新数据出炉！

2022-05-29

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

J Clin Oncol：选择性雌激素受体降解剂（Elacestrant）对比标准内分泌治疗ER+/HR-晚期乳腺癌的疗效：III期临床研究EMERALD

2022-05-26

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

J Immunother Cancer：Bempegaldesleukin联合纳武单抗一线治疗晚期肾细胞癌

2022-04-28

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

Neurology：2017年和2010年修订的McDonald标准在预测临床孤立综合征后MS诊断中的表现

2021-11-01

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

J Clin Oncol：伊布替尼（Ibrutinib）+利妥昔单抗对比安慰剂+ 利妥昔单抗治疗Waldenstrm巨球蛋白血症的疗效:来自随机III期iNNOVATE研究最终分析结果

2021-10-07

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

Clin Cancer Res：国产BTK抑制剂泽布替尼治疗难治/复发性Waldenström巨球蛋白血症的疗效和安全性

2021-09-03

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

Clin Cancer Res：BTK抑制剂Zanubrutinib治疗复发/难治性Waldenströms巨球蛋白血症(WM)的疗效

2021-07-17

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

J Clin Oncol：Bempegaldesleukin 联合纳武利尤单抗（Nivolumab）一线治疗转移性黑色素瘤

2021-07-17

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

美国FDA接受BRUKINSA（Zanubrutinib）治疗Waldenström巨球蛋白血症的补充新药申请

2021-02-20

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

欧洲委员会授予CLR 131治疗Waldenstrom巨球蛋白血症的“孤儿药资格”

2021-01-30

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

Gastroenterology：工程化FGF-19类似物Aldafermin治疗NSAH II期临床获得成功

2021-01-13

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

Bluebird突破性基因疗法Lenti-D申请上市！改善致死罕见病CALD患者长期生存结局

2020-10-06

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

重组白介素2 Aldesleukin治疗肌萎缩性侧索硬化症，获得FDA的孤儿药称号

2020-07-16

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

Waldenström巨球蛋白血症患者同时存在皮肤巨球蛋白病和Buschke硬肿病

2020-06-18

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

Blood：基于代谢状态的癌症治疗方法——Aldh3a2抑制

2020-06-03

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

Galderma的新型透明质酸填充剂Rystylane Kysse，获得FDA批准用于丰唇

2020-05-08

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

Blood：造血细胞移植治疗Wiskott-Aldrich综合征的预后

2020-04-20

科室
- - 订阅+
  - 更多科室
工具
服务